Novo Holdings, along with a group of experienced life science investors, has reinvested in the biotech company Amolyt Pharma. As a result, Novo Holdings is now the largest shareholder in the company.
“We invested in Amolyt in 2019, when parathyroid hormone was still in preclinical stage. It’s amazing to see the company make rapid progress in developing a rare drug for endocrine disease, hypoparathyroidism, where there is a large unmet need and significant market opportunity,” said Naveed Siddiqi, Senior Partner at Novo Holdings and Chairman of Amolyt.
Novo Holdings, one of the leading investors in the life science industry, has again chosen to invest in the Lyon and Boston-based French-American biotech company Amolyt Pharma. This is the third time that Novo Holdings has invested in the company, and this time they have also become the major shareholder.
Amolyt specializes in developing therapeutic peptides for rare hormone diseases and related diseases. Although rare diseases only affect a small portion of the population, they can have serious consequences for patients. Amolyt therefore focuses on developing effective treatments for these patients.
Read more about the story here.
